NCT07213791 - A Study of LY4337713 in Participants With FAP-Positive Solid Tumors | Biotech Hunter

Enrollment

241

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

July 31, 2028

Study Completion Date

March 31, 2033

Conditions

Ovarian NeoplasmsBreast NeoplasmsPancreatic Intraductal NeoplasmsColorectal NeoplasmsEsophageal NeoplasmsStomach NeoplasmsCholangiocarcinoma

Interventions

DRUG

LY4337713

Administered IV.

Trial Locations (16)

10016

New York University (NYU) Clinical Cancer Center, New York

19104

University of Pennsylvania, Philadelphia

19111

Fox Chase Cancer Center, Philadelphia

21061

United Theranostics, Glen Burnie

27710

Duke University Medical Center, Durham

33165

Biogenix Molecular, LLC, Miami

46202

Indiana University (IU) School of Medicine, Indianapolis

48201

Barbara Ann Karmanos Cancer Institute, Detroit

49503

BAMF Health Inc., Grand Rapids

53792

University of Wisconsin - Carbone Cancer Center, Madison

63110

Washington University School of Medicine in St. Louis, St Louis

92663

Hoag Memorial Hospital Presbyterian, Newport Beach

94305

Stanford University Medical Center, Stanford

02114

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

1066 CX

Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL), Amsterdam

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY